Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of DE-111 in Glaucoma/Ocular Hypertension
NCT01343082Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- May 2011
- Primary completion
- Mar 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of tafluprost, timolol in open-angle glaucoma (OAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started May 2011; status: completed.
02
Drugs
tafluprosttimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01343082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01343082.